User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Primary tabs

Langley, Richard G Elewski, Boni E Lebwohl, Mark Reich, Kristian Griffiths, Christopher E M Ghislain, Pierre-Dominique [UCL] Papavassilis, Charis

Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2014
Language Anglais
Journal information "New England Journal of Medicine" - Vol. 371, no.4, p. 326-338 (2014)
Peer reviewed yes
Publisher Massachusetts Medical Society (Boston)
issn 0028-4793
e-issn 1533-4406
Affiliation UCL - Autre
MESH Subject Adult ; Infection ; Injections, Subcutaneous ; Interleukin-17 ; Male ; Middle Aged ; Psoriasis ; Receptors, Tumor Necrosis Factor ; Antibodies ; Antibodies, Monoclonal ; Double-Blind Method ; Female ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Immunosuppressive Agents
Links
Bibliographic reference Langley, Richard G ; Elewski, Boni E ; Lebwohl, Mark ; Reich, Kristian ; Griffiths, Christopher E M ; et. al. Secukinumab in plaque psoriasis--results of two phase 3 trials.. In: New England Journal of Medicine, Vol. 371, no.4, p. 326-338 (2014)
Permanent URL http://hdl.handle.net/2078.1/157510